A Phase 3 interventional study of Custodiol-N and Custodiol in Heart Failure, sponsored by Dr. F. Köhler Chemie GmbH. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by Dr. F. Köhler Chemie GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 600 studies in Heart Failure with a site in Germany — 107 open to participants now, 137 under way, 19 of them phase 3. Heart Failure · Germany.
Among the 600 studies in Heart Failure with a site in Germany, this one is the 232nd largest by enrollment of the 386 interventional ones that give a count, is one of 30 that started in 2016, is one of 81 in phase 3, and was the 274th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →107 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Germany
Ages 18+
Stephan Baldus · Sites in Germany
Ages 18+
Jena University Hospital · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 29 more countries
Ages 18+
AstraZeneca · Sites in Germany, United States, Portugal and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
600 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 82 · Phase 3 91 · Phase 4 32
First in 1983; this study’s year is marked. 30 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 161 across the 386 interventional studies, 286 across the 212 observational. Of the 411 that completed or were terminated, 126 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
356 of 600 have an industry lead sponsor. The 10 most frequent:
Dr. F. Köhler Chemie GmbH is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Dr. F. Köhler Chemie GmbH has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
35 of the studies in Heart Failure with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07038356Phase 3Christian SchulzeEffects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure | 2027-04-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 35 to your calendar (.ics) → With an account.
Among the 600 studies in Heart Failure with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this investigation is to demonstrate non-inferiority in outcome of Custodiol-N against Custodiol in heart transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Donor criteria:
Exclusion Criteria:
Donor criteria:
Patient criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
Drug: Custodiol-N · Procedure: organ perfusion for heart transplantation
comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
Drug: Custodiol · Procedure: organ perfusion for heart transplantation
comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Drug pages: Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride
comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Creatine kinase Myocard type "CK-MB" peak value
day 1: measurements 4, 8, 12, 16, 20, 24 hours ± 30 min; day 2-3: measurements 8, 16 and 24 hours ± 2 hours; day 4-7 one time/day
Time frame: from 4 to 168 hours after release of the aortic cross clamp
Catecholamine requirement
defined as "yes" or "no"
Time frame: from entry to the trial up to day 7
Patient survival
Time frame: at 7 days and 1, 3 and 12 months
Complications
occurrence, severity, type, and duration
Time frame: from the time of the transplantation up to day 7
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2016 to primary completion in Sep 2019, 38 months.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 38 months is close to that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Custodiol-N solution · Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride
Dr. F. Köhler Chemie GmbH